Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[14C] Omaveloxolone ADME Study in Healthy Males
NCT03931590Phase 1Completed
- Sponsor
- Biogen
- Start
- Apr 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of omaveloxolone in Friedreich's ataxia (FA), sponsored by Biogen. Primary endpoints: Maximum concentration of omaveloxolone at 22 days, Area under the omaveloxolone concentration-time curve at 22 days and 4 more. Started Apr 2019; status: completed.
02
Drugs
omaveloxolone
03
Conditions
Friedreich's ataxia (FA)
Beyond the preview
Go deeper on NCT03931590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03931590.